San Diego—Patients undergoing surgery with detectable levels of a tumor necrosis factor (TNF) inhibitor are not at increased risk for postoperative infection, according to one of the largest prospective studies to address this issue.
Based on the findings, “preoperative use of a TNF inhibitor should not affect the decision to perform surgery in most IBD patients,” concluded Benjamin L. Cohen, MD, an associate professor of medicine at the Icahn School of Medicine at Mount Sinai